BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Imzokitug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Imzokitug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07226856-2544@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Imzokitug: Phase 2 readout est. (NCT07226856)
DESCRIPTION:Imzokitug\, phase 2.\nStudy: BMS-986340 in Combination With Niv
 olumab\, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic an
 d Recurrent Pancreatic Adenocarcinoma\nEstimated primary completion: 28 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/imzokitu
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 226856
URL:https://assetmemo.bio/drug/imzokitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680764-2544@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Imzokitug: Phase 2 readout est. (NCT07680764)
DESCRIPTION:Imzokitug\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy To Assess the Safety\, Tolerability\, and Efficacy of Imzokitug in Comb
 ination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pum
 itamig and PDCT as First-line Treatment for Participants With Locally Adva
 nced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 15 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/imzokitug#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07680764
URL:https://assetmemo.bio/drug/imzokitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-2544@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Imzokitug: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Imzokitug\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/imzokitug#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/imzokitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
